Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections

PloS One
Nattawan PalavutitotaiNasikarn Angkasekwinai

Abstract

The incidence of nosocomial infections from extensively drug-resistant Pseudomonas aeruginosa (XDR-PA) has been increasing worldwide. We investigated the prevalence and factors associated with XDR-PA infections, including the factors that predict mortality. We retrospectively studied a cohort of adult, hospitalized patients with P. aeruginosa (PA) infections between April and December 2014. Of the 255 patients with PA infections, 56 (22%) were due to XDR-PA, 32 (12.5%) to multidrug resistant Pseudomonas aeruginosa (MDR-PA), and 167 (65.5%) to non-MDR PA. Receiving total parenteral nutrition (adjusted OR [aOR] 6.21; 95% CI 1.05-36.70), prior carbapenem use (aOR 4.88; 95% CI 2.36-10.08), and prior fluoroquinolone use (aOR 3.38; 95% CI 1.44-7.97) were independently associated with the XDR-PA infections. All XDR-PA remained susceptible to colistin. Factors associated with mortality attributable to the infections were the presence of sepsis/septic shock (aOR 11.60; 95% CI 4.66-28.82), admission to a medical department (aOR 4.67; 95% CI 1.81-12.06), receiving a central venous catheter (aOR 3.78; 95% CI 1.50-9.57), and XDR-PA infection (aOR 2.73; 95% CI 1.05-7.08). The prevalence of XDR-PA infections represented almost a quarter of Ps...Continue Reading

References

Jun 1, 1988·American Journal of Infection Control·J S GarnerJ M Hughes
Sep 5, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cheol-In KangKang-Won Choe
Apr 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Matthew E Falagas, Sofia K Kasiakou
Jun 28, 2006·Antimicrobial Agents and Chemotherapy·Matthew E FalagasArgyris Michalopoulos
Feb 20, 2007·International Journal of Antimicrobial Agents·Matthew E Falagas, Ioannis A Bliziotis
Mar 3, 2007·The European Respiratory Journal·I I SiemposM E Falagas
Sep 20, 2007·The Journal of Antimicrobial Chemotherapy·Alexandre Prehn ZavasckiRoger L Nation
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Matthew E Falagas, Drosos E Karageorgopoulos
Oct 11, 2008·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·N PetrosilloM E Falagas
Jun 13, 2009·The Journal of Antimicrobial Chemotherapy·Ali A El Solh, Ahmad Alhajhusain
Aug 19, 2010·Expert Review of Pharmacoeconomics & Outcomes Research·Elizabeth B Hirsch, Vincent H Tam
Jul 29, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A-P MagiorakosD L Monnet
May 4, 2012·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C PeñaJ Ariza
Jun 26, 2012·The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases·Marisa Zenaide Ribeiro GomesMarise Dutra Asensi
Jul 17, 2012·American Journal of Infection Control·Yin-Xin LiewAndrea L Kwa
Dec 12, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Dawn M SievertUNKNOWN National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities
Jan 3, 2013·Microbiology and Immunology·Piyatip KhuntayapornMullika Traidej Chomnawang
Jan 25, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C PeñaJ Ariza
Aug 7, 2013·Antimicrobial Agents and Chemotherapy·Oren ZusmanMical Paul
Sep 3, 2014·American Journal of Infection Control·Víctor Daniel RosenthalUNKNOWN International Nosocomial Infection Control Consortium
Oct 22, 2016·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Lindsey M WeinerDawn M Sievert

❮ Previous
Next ❯

Citations

Oct 1, 2019·Current Opinion in Infectious Diseases·Almudena BurilloEmilio Bouza
Jul 19, 2019·American Journal of Respiratory Cell and Molecular Biology·Yung Jin JeonHyun Jik Kim
Sep 11, 2019·The Journal of Antimicrobial Chemotherapy·Melissa G McCrackenUNKNOWN Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD
Apr 10, 2019·Antibiotics·Emily M Eichenberger, Joshua T Thaden
Apr 17, 2019·Frontiers in Microbiology·Mansura S MulaniKarishma R Pardesi
May 7, 2021·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Korakrit ImwattanaThomas V Riley
Jun 17, 2021·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Alexander G BobrovVlado Antonic
Jun 29, 2021·Antimicrobial Agents and Chemotherapy·Thitiya YungyuenUNKNOWN Research University Network Thailand Study Group
Jul 27, 2021·Current Opinion in Infectious Diseases·Sabina HerreraAlex Soriano

❮ Previous
Next ❯

Software Mentioned

NQuery Advisor
PASW Statistics
SPSS

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.